Cargando…

Design, Synthesis, In Silico Studies and In Vitro Evaluation of New Indole- and/or Donepezil-like Hybrids as Multitarget-Directed Agents for Alzheimer’s Disease

Alzheimer’s disease (AD) is considered a complex neurodegenerative condition which warrants the development of multitargeted drugs to tackle the key pathogenetic mechanisms of the disease. In this study, two novel series of melatonin- and donepezil-based hybrid molecules with hydrazone (3a–r) or sul...

Descripción completa

Detalles Bibliográficos
Autores principales: Angelova, Violina T., Georgiev, Borislav, Pencheva, Tania, Pajeva, Ilza, Rangelov, Miroslav, Todorova, Nadezhda, Zheleva-Dimitrova, Dimitrina, Kalcheva-Yovkova, Elena, Valkova, Iva V., Vassilev, Nikolay, Mihaylova, Rositsa, Stefanova, Denitsa, Petrov, Boris, Voynikov, Yulian, Tzankova, Virginia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10534827/
https://www.ncbi.nlm.nih.gov/pubmed/37765003
http://dx.doi.org/10.3390/ph16091194
_version_ 1785112485859164160
author Angelova, Violina T.
Georgiev, Borislav
Pencheva, Tania
Pajeva, Ilza
Rangelov, Miroslav
Todorova, Nadezhda
Zheleva-Dimitrova, Dimitrina
Kalcheva-Yovkova, Elena
Valkova, Iva V.
Vassilev, Nikolay
Mihaylova, Rositsa
Stefanova, Denitsa
Petrov, Boris
Voynikov, Yulian
Tzankova, Virginia
author_facet Angelova, Violina T.
Georgiev, Borislav
Pencheva, Tania
Pajeva, Ilza
Rangelov, Miroslav
Todorova, Nadezhda
Zheleva-Dimitrova, Dimitrina
Kalcheva-Yovkova, Elena
Valkova, Iva V.
Vassilev, Nikolay
Mihaylova, Rositsa
Stefanova, Denitsa
Petrov, Boris
Voynikov, Yulian
Tzankova, Virginia
author_sort Angelova, Violina T.
collection PubMed
description Alzheimer’s disease (AD) is considered a complex neurodegenerative condition which warrants the development of multitargeted drugs to tackle the key pathogenetic mechanisms of the disease. In this study, two novel series of melatonin- and donepezil-based hybrid molecules with hydrazone (3a–r) or sulfonyl hydrazone (5a–l) fragments were designed, synthesized, and evaluated as multifunctional ligands against AD-related neurodegenerative mechanisms. Two lead compounds (3c and 3d) exhibited a well-balanced multifunctional profile, demonstrating intriguing acetylcholinesterase (AChE) inhibition, promising antioxidant activity assessed by DPPH, ABTS, and FRAP methods, as well as the inhibition of lipid peroxidation in the linoleic acid system. Compound 3n, possessing two indole scaffolds, showed the highest activity against butyrylcholinesterase (BChE) and a high selectivity index (SI = 47.34), as well as a pronounced protective effect in H(2)O(2)-induced oxidative stress in SH-SY5Y cells. Moreover, compounds 3c, 3d, and 3n showed low neurotoxicity against malignant neuroblastoma cell lines of human (SH-SY5Y) and murine (Neuro-2a) origin, as well as normal murine fibroblast cells (CCL-1) that indicate the in vitro biocompatibility of the experimental compounds. Furthermore, compounds 3c, 3d, and 3n were capable of penetrating the blood–brain barrier (BBB) in the experimental PAMPA-BBB study. The molecular docking showed that compound 3c could act as a ligand to both MT1 and MT2 receptors, as well as to AchE and BchE enzymes. Taken together, those results outline compounds 3c, 3d, and 3n as promising prototypes in the search of innovative compounds for the treatment of AD-associated neurodegeneration with oxidative stress. This study demonstrates that hydrazone derivatives with melatonin and donepezil are appropriate for further development of new AChE/BChE inhibitory agents.
format Online
Article
Text
id pubmed-10534827
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-105348272023-09-29 Design, Synthesis, In Silico Studies and In Vitro Evaluation of New Indole- and/or Donepezil-like Hybrids as Multitarget-Directed Agents for Alzheimer’s Disease Angelova, Violina T. Georgiev, Borislav Pencheva, Tania Pajeva, Ilza Rangelov, Miroslav Todorova, Nadezhda Zheleva-Dimitrova, Dimitrina Kalcheva-Yovkova, Elena Valkova, Iva V. Vassilev, Nikolay Mihaylova, Rositsa Stefanova, Denitsa Petrov, Boris Voynikov, Yulian Tzankova, Virginia Pharmaceuticals (Basel) Article Alzheimer’s disease (AD) is considered a complex neurodegenerative condition which warrants the development of multitargeted drugs to tackle the key pathogenetic mechanisms of the disease. In this study, two novel series of melatonin- and donepezil-based hybrid molecules with hydrazone (3a–r) or sulfonyl hydrazone (5a–l) fragments were designed, synthesized, and evaluated as multifunctional ligands against AD-related neurodegenerative mechanisms. Two lead compounds (3c and 3d) exhibited a well-balanced multifunctional profile, demonstrating intriguing acetylcholinesterase (AChE) inhibition, promising antioxidant activity assessed by DPPH, ABTS, and FRAP methods, as well as the inhibition of lipid peroxidation in the linoleic acid system. Compound 3n, possessing two indole scaffolds, showed the highest activity against butyrylcholinesterase (BChE) and a high selectivity index (SI = 47.34), as well as a pronounced protective effect in H(2)O(2)-induced oxidative stress in SH-SY5Y cells. Moreover, compounds 3c, 3d, and 3n showed low neurotoxicity against malignant neuroblastoma cell lines of human (SH-SY5Y) and murine (Neuro-2a) origin, as well as normal murine fibroblast cells (CCL-1) that indicate the in vitro biocompatibility of the experimental compounds. Furthermore, compounds 3c, 3d, and 3n were capable of penetrating the blood–brain barrier (BBB) in the experimental PAMPA-BBB study. The molecular docking showed that compound 3c could act as a ligand to both MT1 and MT2 receptors, as well as to AchE and BchE enzymes. Taken together, those results outline compounds 3c, 3d, and 3n as promising prototypes in the search of innovative compounds for the treatment of AD-associated neurodegeneration with oxidative stress. This study demonstrates that hydrazone derivatives with melatonin and donepezil are appropriate for further development of new AChE/BChE inhibitory agents. MDPI 2023-08-22 /pmc/articles/PMC10534827/ /pubmed/37765003 http://dx.doi.org/10.3390/ph16091194 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Angelova, Violina T.
Georgiev, Borislav
Pencheva, Tania
Pajeva, Ilza
Rangelov, Miroslav
Todorova, Nadezhda
Zheleva-Dimitrova, Dimitrina
Kalcheva-Yovkova, Elena
Valkova, Iva V.
Vassilev, Nikolay
Mihaylova, Rositsa
Stefanova, Denitsa
Petrov, Boris
Voynikov, Yulian
Tzankova, Virginia
Design, Synthesis, In Silico Studies and In Vitro Evaluation of New Indole- and/or Donepezil-like Hybrids as Multitarget-Directed Agents for Alzheimer’s Disease
title Design, Synthesis, In Silico Studies and In Vitro Evaluation of New Indole- and/or Donepezil-like Hybrids as Multitarget-Directed Agents for Alzheimer’s Disease
title_full Design, Synthesis, In Silico Studies and In Vitro Evaluation of New Indole- and/or Donepezil-like Hybrids as Multitarget-Directed Agents for Alzheimer’s Disease
title_fullStr Design, Synthesis, In Silico Studies and In Vitro Evaluation of New Indole- and/or Donepezil-like Hybrids as Multitarget-Directed Agents for Alzheimer’s Disease
title_full_unstemmed Design, Synthesis, In Silico Studies and In Vitro Evaluation of New Indole- and/or Donepezil-like Hybrids as Multitarget-Directed Agents for Alzheimer’s Disease
title_short Design, Synthesis, In Silico Studies and In Vitro Evaluation of New Indole- and/or Donepezil-like Hybrids as Multitarget-Directed Agents for Alzheimer’s Disease
title_sort design, synthesis, in silico studies and in vitro evaluation of new indole- and/or donepezil-like hybrids as multitarget-directed agents for alzheimer’s disease
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10534827/
https://www.ncbi.nlm.nih.gov/pubmed/37765003
http://dx.doi.org/10.3390/ph16091194
work_keys_str_mv AT angelovaviolinat designsynthesisinsilicostudiesandinvitroevaluationofnewindoleandordonepezillikehybridsasmultitargetdirectedagentsforalzheimersdisease
AT georgievborislav designsynthesisinsilicostudiesandinvitroevaluationofnewindoleandordonepezillikehybridsasmultitargetdirectedagentsforalzheimersdisease
AT penchevatania designsynthesisinsilicostudiesandinvitroevaluationofnewindoleandordonepezillikehybridsasmultitargetdirectedagentsforalzheimersdisease
AT pajevailza designsynthesisinsilicostudiesandinvitroevaluationofnewindoleandordonepezillikehybridsasmultitargetdirectedagentsforalzheimersdisease
AT rangelovmiroslav designsynthesisinsilicostudiesandinvitroevaluationofnewindoleandordonepezillikehybridsasmultitargetdirectedagentsforalzheimersdisease
AT todorovanadezhda designsynthesisinsilicostudiesandinvitroevaluationofnewindoleandordonepezillikehybridsasmultitargetdirectedagentsforalzheimersdisease
AT zhelevadimitrovadimitrina designsynthesisinsilicostudiesandinvitroevaluationofnewindoleandordonepezillikehybridsasmultitargetdirectedagentsforalzheimersdisease
AT kalchevayovkovaelena designsynthesisinsilicostudiesandinvitroevaluationofnewindoleandordonepezillikehybridsasmultitargetdirectedagentsforalzheimersdisease
AT valkovaivav designsynthesisinsilicostudiesandinvitroevaluationofnewindoleandordonepezillikehybridsasmultitargetdirectedagentsforalzheimersdisease
AT vassilevnikolay designsynthesisinsilicostudiesandinvitroevaluationofnewindoleandordonepezillikehybridsasmultitargetdirectedagentsforalzheimersdisease
AT mihaylovarositsa designsynthesisinsilicostudiesandinvitroevaluationofnewindoleandordonepezillikehybridsasmultitargetdirectedagentsforalzheimersdisease
AT stefanovadenitsa designsynthesisinsilicostudiesandinvitroevaluationofnewindoleandordonepezillikehybridsasmultitargetdirectedagentsforalzheimersdisease
AT petrovboris designsynthesisinsilicostudiesandinvitroevaluationofnewindoleandordonepezillikehybridsasmultitargetdirectedagentsforalzheimersdisease
AT voynikovyulian designsynthesisinsilicostudiesandinvitroevaluationofnewindoleandordonepezillikehybridsasmultitargetdirectedagentsforalzheimersdisease
AT tzankovavirginia designsynthesisinsilicostudiesandinvitroevaluationofnewindoleandordonepezillikehybridsasmultitargetdirectedagentsforalzheimersdisease